Astel­las pulls law­suit over price ne­go­ti­a­tions as Xtan­di side­steps first list of 10 drugs

Astel­las on Wednes­day vol­un­tar­i­ly dis­missed its law­suit against the Biden ad­min­is­tra­tion’s HHS af­ter its prostate can­cer drug Xtan­di (en­za­lu­tamide) was not in­clud­ed in the ini­tial list of drugs that will face price ne­go­ti­a­tions in 2026.

Astel­las said in a state­ment on Wednes­day af­ter­noon:

[The de­ci­sion] does not change our fun­da­men­tal be­lief that in its cur­rent form, the Medicare Drug Price Ne­go­ti­a­tion Pro­gram (Pro­gram) cre­at­ed by the IRA is bad pol­i­cy and un­con­sti­tu­tion­al. The price-set­ting poli­cies in the Pro­gram will dis­rupt the com­pet­i­tive mar­ket­place for pre­scrip­tion drugs in the U.S., dis­in­cen­tivize crit­i­cal re­search and de­vel­op­ment ef­forts for hard-to-treat con­di­tions, and di­min­ish the avail­abil­i­ty of new med­i­cines for pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER